This content is machine translated Dapagliflozin for T2D and heart failure Epicardial fat reduced in patients with type 2 diabetes and HF The co-occurrence of heart failure (HF) and diabetes leads to a higher risk of complications, higher mortality and worse outcomes than either disease alone. Studies have shown the importance of...…
View Post 5 min This content is machine translated Clinical relevance, benefits and limitations Atrial Fibrillation Screening Screening for atrial fibrillation is considered a potentially effective strategy for preventing strokes at an early stage. But how great is the actual benefit in clinical care? A recent meta-analysis...…
View Post 9 min This content is machine translated Type 2 diabetes and heart failure: a bidirectional relationship Proactive preventive measures can reduce the burden of disease Heart failure and diabetes mellitus are two of the greatest global health burdens and their prevalence is steadily increasing. At the same time, heart failure is becoming one of the...…
View Post 9 min This content is machine translated Evidence, pathophysiology and management in the light of current data Heart failure with improved ejection fraction (HFimpEF) In recent years, Heart Failure with Improved Ejection Fraction (HFimpEF) has developed into a clinical entity in its own right, which is being considered in an increasingly differentiated manner. With...…
View Post 20 min This content is machine translated AI in neurology Control instead of a flood of data: AI makes big data and wearables usable Artificial intelligence has become a key technology in medicine, including in complex neurology. Modern methods such as machine learning and deep learning in combination with data and wearables (wearable sensor...… CME-Test
View Post 10 min This content is machine translated Mechanisms, evidence and therapeutic consequences GLP-1 receptor agonists in cardiology GLP-1 receptor agonists (GLP-1RAs) have rapidly evolved from antidiabetic drugs to cardiometabolic therapies with clinically proven reductions in hard cardiovascular endpoints – and increasingly beyond the traditional diabetes population. The...…
View Post 7 min This content is machine translated Arterial elasticity, vascular ageing, endothelial function Longevity and cardiovascular health 2025 Vascular ageing is not a purely “biological” concept, but can be measured clinically – via arterial stiffness (e.g. PWV), endothelial function (e.g. FMD) and the resulting risk profiles. In parallel...…
View Post 9 min This content is machine translated Pathophysiology, cardiovascular consequences and metabolic interventions Obesity accelerates cardiovascular ageing Obesity and demographic ageing are two global megatrends that overlap in a particularly unfavorable way in the cardiovascular system. Both factors independently increase the risk of cardiovascular disease, but also...…
View Post 7 min This content is machine translated Atrial fibrillation: interdisciplinary effort is crucial Managing risk factors and comorbidities in addition to rhythm control The previously used “ABC” scheme was replaced by the more comprehensive “CARE” approach in the ESC guideline published in 2024. Drug therapy for atrial fibrillation is primarily aimed at preventing...…
View Post 11 min This content is machine translated From statins to metformin Preventive pharmacology and longevity In medicine, “longevity” is now less anti-ageing marketing than a very specific question of precision prevention: which pharmacological interventions prevent (or delay) cardiometabolic, renal, oncological and functional endpoints – and...…
View Post 6 min This content is machine translated Lipid management: ESC/EAS guideline update 2025 New recommendations on CVD risk classification, lipid lowering in statin intolerance and hoFH The European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) guideline update on the management of dyslipidemia continues to focus largely on how best to manage lipid levels to...…
